KORS

Cara Therapeutics to Present at the Piper Sandler 33rd Annual Virtual Healthcare Conference

Retrieved on: 
Thursday, November 18, 2021
Patient, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Conference, Company, News, Chronic kidney disease, KORS, Atopic dermatitis, Nasdaq, KOR, GLOBE, Itch, Piper Sandler Companies, FDA, Therapy, Primary biliary cholangitis, Food, CKD, Pharmaceutical industry

The fireside chat will be available beginning Monday, November 22, 2021 at 10:00 a.m.

Key Points: 
  • The fireside chat will be available beginning Monday, November 22, 2021 at 10:00 a.m.
  • A webcast of the fireside chat can be accessed under "Events & Presentations" in the News & Investors section of the Company's website at www.CaraTherapeutics.com.
  • An archived webcast recording will be available on the Cara website for approximately 30 days.
  • Cara Therapeutics is an early commercial-stage biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus by selectively targeting peripheral kappa opioid receptors, or KORs.

Cara Therapeutics to Present at Upcoming Investor Conferences

Retrieved on: 
Tuesday, November 9, 2021
NP, Webcast, CKD, Therapy, AD, News, PBC, Conference, Company, GLOBE, Itch, KORS, Nasdaq, Patient, KOR, FDA, Pharmaceutical industry

Archived webcast recordings will be available on the Cara website for approximately 30 days.

Key Points: 
  • Archived webcast recordings will be available on the Cara website for approximately 30 days.
  • Cara Therapeutics is an early commercial-stage biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus by selectively targeting peripheral KORs.
  • Cara is developing a novel and proprietary class of product candidates, led by KORSUVA (CR845/difelikefalin), a first-in-class KOR agonist that targets the bodys peripheral nervous system, as well as certain immune cells.
  • KORSUVA injection was approved by the FDA for the treatment of moderate-to-severe CKD-aP in adults undergoing hemodialysis on August 23, 2021.

Cara Therapeutics Reports Third Quarter 2021 Financial Results

Retrieved on: 
Monday, November 8, 2021
Safety, Achievement, Priority review, Oral, Therapy, CMS, Medicare, KARE, Non, MAA, Food and Drug Administration, European Union, CEO, Leo Pharma, EMA, Food, European Medicines Agency, Union, Centers for Medicare & Medicaid Services, Chronic kidney disease, Dialysis, Conference call, Â, Doctor of Philosophy, Patient, Conference, Company, Marketing, GLOBE, Itch, New Drug Application, Diagnosis, BSA, KORS, Nasdaq, Atopic dermatitis, FDA, Health care, Documentation, Pharmaceutical industry, Management

STAMFORD, Conn., Nov. 08, 2021 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus by selectively targeting peripheral kappa opioid receptors (KORs), today announced financial results and operational highlights for the third quarter ended September 30, 2021.

Key Points: 
  • ET
    STAMFORD, Conn., Nov. 08, 2021 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus by selectively targeting peripheral kappa opioid receptors (KORs), today announced financial results and operational highlights for the third quarter ended September 30, 2021.
  • In the third quarter of 2021, Cara made significant progress across our development programs, culminating with the FDA approval of KORSUVA injection for moderate-to-severe pruritus associated with chronic kidney disease in hemodialysis patients, said Derek Chalmers, Ph.D., D.Sc., President and Chief Executive Officer of Cara Therapeutics.
  • Third Quarter and Recent Developments:
    In November 2021, the Company announced the appointment of Christopher Posner as President and Chief Executive Officer of Cara Therapeutics, effective November 9, 2021.
  • ET to discuss third quarter 2021 financial results and provide a business update.

Cara Therapeutics Announces CEO Transition

Retrieved on: 
Wednesday, November 3, 2021
Leo Pharma, KORS, KOR, IV, Â, Dermatology, Duke University, Fuqua School, Bristol Myers Squibb, Rosacea, Security (finance), U.S. Securities and Exchange Commission, Patient, Private Securities Litigation Reform Act, Psoriasis, FDA, Food, Pfizer, LEO, Triple accreditation, Regulation of tobacco by the U.S. Food and Drug Administration, Chronic kidney disease, Senior advisor, Oral, Atopic dermatitis, Marketing, LLC, Company, Risk, CEO, Economics, Growth, CKD, Nasdaq, Therapy, Villanova University, Itch, GLOBE, Business, Primary biliary cholangitis, Pharmaceutical industry

On behalf of the Cara board, I would like to thank Derek for all of his invaluable contributions to Cara from founding the Company through to FDA approval of the Companys lead product, KORSUVA injection, said Martin Vogelbaum, Lead Independent Director of Cara Therapeutics.

Key Points: 
  • On behalf of the Cara board, I would like to thank Derek for all of his invaluable contributions to Cara from founding the Company through to FDA approval of the Companys lead product, KORSUVA injection, said Martin Vogelbaum, Lead Independent Director of Cara Therapeutics.
  • Cara Therapeutics is a clinical-stage biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus by selectively targeting peripheral kappa opioid receptors, or KORs.
  • Risks are described more fully in Cara Therapeutics filings with the Securities and Exchange Commission, including the "Risk Factors" section of Cara Therapeutics Annual Report on Form 10-K for the year ended December 31, 2020 and its other documents subsequently filed with or furnished to the Securities and Exchange Commission.
  • Except to the extent required by law, Cara Therapeutics undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.

Cara Therapeutics to Announce Third Quarter 2021 Financial Results on November 8, 2021

Retrieved on: 
Monday, November 1, 2021
KOR, KORS, Patient, FDA, Food, ID, Chronic kidney disease, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Atopic dermatitis, Company, CKD, Nasdaq, Therapy, News, Itch, GLOBE, Primary biliary cholangitis, Pharmaceutical industry

ET to report third quarter 2021 financial results and provide a corporate update.

Key Points: 
  • ET to report third quarter 2021 financial results and provide a corporate update.
  • To participate in the conference call, please dial (855) 445-2816 (domestic) or (484) 756-4300 (international) and refer to conference ID 1480703.
  • An archived webcast recording will be available on the Cara website beginning approximately two hours after the call.
  • Cara Therapeutics is a clinical-stage biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus by selectively targeting peripheral kappa opioid receptors, or KORs.

Cara Therapeutics Announces Late-Breaking Presentation at 2021 European Academy of Dermatology and Venereology (EADV) Virtual Congress

Retrieved on: 
Wednesday, September 29, 2021
Food, Therapy, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Journal of the European Academy of Dermatology and Venereology, Congress, FDA, Patient, Primary biliary cholangitis, Washington University School of Medicine, AD, Itch, KOR, KORS, Atopic dermatitis, KARE, Oral, CKD, Nasdaq, Chronic kidney disease, GLOBE, Pharmaceutical industry

Details for the late-breaking oral presentation are as follows:

Key Points: 
  • Details for the late-breaking oral presentation are as follows:
    Presenter: Brian S. Kim, MD, MTR, Washington University School of Medicine, St. Louis, MO
    Cara Therapeutics is a clinical-stage biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus by selectively targeting peripheral kappa opioid receptors, or KORs.
  • Cara is developing a novel and proprietary class of product candidates, led by KORSUVA (CR845/difelikefalin), a first-in-class KOR agonist that targets the bodys peripheral nervous system, as well as certain immune cells.
  • KORSUVA Injection was approved by the U.S. Food and Drug Administration (FDA) for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD-aP) in adults undergoing hemodialysis on August 23, 2021.
  • Oral KORSUVA has completed Phase 2 trials for the treatment of pruritus in patients with CKD and atopic dermatitis and is currently in Phase 2 trials in primary biliary cholangitis and notalgia paresthetica patients with moderate-to-severe pruritus.

Cara Therapeutics to Present at the the 2021 Cantor Virtual Global Healthcare Conference

Retrieved on: 
Friday, September 24, 2021
Food, Therapy, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Conference, News, Doctor of Philosophy, FDA, Patient, Primary biliary cholangitis, Itch, Company, KOR, KORS, Atopic dermatitis, CKD, Nasdaq, Chronic kidney disease, GLOBE, Pharmaceutical industry

STAMFORD, Conn., Sept. 24, 2021 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc.(Nasdaq: CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus by selectively targeting peripheral kappa opioid receptors (KORs), today announced that Derek Chalmers, Ph.D., D.Sc., President and Chief Executive Officer, will participate in a fireside chat at the 2021 Cantor Virtual Global Healthcare Conference on Tuesday, September 28, 2021 at 3.20 p.m.

Key Points: 
  • STAMFORD, Conn., Sept. 24, 2021 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc.(Nasdaq: CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus by selectively targeting peripheral kappa opioid receptors (KORs), today announced that Derek Chalmers, Ph.D., D.Sc., President and Chief Executive Officer, will participate in a fireside chat at the 2021 Cantor Virtual Global Healthcare Conference on Tuesday, September 28, 2021 at 3.20 p.m.
  • A live webcast of the fireside chat can be accessed under "Events & Presentations" in the News & Investors section of the Company's website at www.CaraTherapeutics.com .
  • An archived webcast recording will be available on the Cara website for approximately 30 days.
  • Cara Therapeutics is a clinical-stage biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus by selectively targeting peripheral kappa opioid receptors, or KORs.

Cara Therapeutics Reports Second Quarter 2021 Financial Results

Retrieved on: 
Monday, August 9, 2021
EMA, KORS, United, Cara, Population, GLOBE, FDA, Food and Drug Administration, Therapy, NDA, Nasdaq, MAA, ITT, Union, European Medicines Agency, International, Prescription Drug User Fee Act, Priority review, Chronic kidney disease, DCA Design International Ltd, Achievement, Patient, Itch, Oral, BSA, Marketing, Conference, KARE, CKD, Doctor of Philosophy, Food, PDUFA, New Drug Application, Conference call, Company, European Union, Pharmaceutical industry

STAMFORD, Conn., Aug. 09, 2021 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus by selectively targeting peripheral kappa opioid receptors (KORs), today announced financial results and operational highlights for the second quarter ended June 30, 2021.

Key Points: 
  • ET
    STAMFORD, Conn., Aug. 09, 2021 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus by selectively targeting peripheral kappa opioid receptors (KORs), today announced financial results and operational highlights for the second quarter ended June 30, 2021.
  • Second Quarter and Recent Developments:
    In February 2021, the FDA accepted the filing of the NDA for KORSUVA Injection for the treatment of moderate-to-severe pruritus in hemodialysis patients.
  • The EMA is expected to render a decision on the EU MAA in the second quarter of 2022.
  • ET to discuss second quarter 2021 financial results and provide a business update.